Immunovia AB (publ) (STO:IMMNOV)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.5420
+0.0110 (2.07%)
Aug 13, 2025, 5:29 PM CET
2.07%
Market Cap162.53M
Revenue (ttm)914.00K
Net Income (ttm)-131.39M
Shares Out306.08M
EPS (ttm)-1.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,111,100
Average Volume5,340,624
Open0.5400
Previous Close0.5310
Day's Range0.5380 - 0.5590
52-Week Range0.2440 - 2.3500
Beta2.70
RSI49.25
Earnings DateAug 21, 2025

About Paycor HCM

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2007
Employees 9
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMNOV
Full Company Profile

Financial Performance

In 2024, Immunovia AB's revenue was 931,000, a decrease of -40.89% compared to the previous year's 1.58 million. Losses were -76.54 million, -75.26% less than in 2023.

Financial Statements

News

Immunovia AB (LTS:0G8X) Q4 2024 Earnings Call Highlights: Breakthroughs in Testing and ...

Immunovia AB (LTS:0G8X) Q4 2024 Earnings Call Highlights: Breakthroughs in Testing and Financial Stability Amid Market Challenges

6 months ago - GuruFocus

Q4 2024 Immunovia AB (publ) Earnings Call Transcript

Q4 2024 Immunovia AB (publ) Earnings Call Transcript

6 months ago - GuruFocus

Immunovia reports Q4 results

6 months ago - Seeking Alpha

Immunovia initiates search for a new CFO

6 months ago - Seeking Alpha

Q3 2024 Immunovia AB (publ) Earnings Call Transcript

Q3 2024 Immunovia AB (publ) Earnings Call Transcript

9 months ago - GuruFocus